Maurizio Lucchesi1, Gaetano Lanzetta2, Andrea Antonuzzo3, Antonio Rozzi4, Iacopo Sardi5, Claudio Favre6, Carla Ida Ripamonti7, Daniele Santini8, Grazia Armento9. 1. Thoracic Cancer Centre, Pulmonology Unit, University Hospital of Pisa, Pisa, Italy; Department of Pediatric Oncology and Hematology, Anna Meyer Children's University Hospital, Florence, Italy. Electronic address: mauriziolucchesi84@gmail.com. 2. Medical Oncology Unit, IRCCS Neuromed, Pozzilli, Italy; Medical Oncology Unit, Italian Neuro-Traumatology Institute, Grottaferrata, Italy. Electronic address: g_lanzetta58@hotmail.com. 3. Medical Oncology Unit 1 SSN, Pisa University Hospital, Pisa, Italy. Electronic address: andrea.antonuzzo@tin.it. 4. Medical Oncology Unit, Italian Neuro-Traumatology Institute, Grottaferrata, Italy. Electronic address: antoniorozzi@virgilio.it. 5. Department of Pediatric Oncology and Hematology, Anna Meyer Children's University Hospital, Florence, Italy. Electronic address: iacopo.sardi@meyer.it. 6. Department of Pediatric Oncology and Hematology, Anna Meyer Children's University Hospital, Florence, Italy. Electronic address: claudio.favre@meyer.it. 7. Supportive Care in Cancer Unit, IRCCS National Cancer Institute, Milan, Italy. Electronic address: carla.ripamonti@istitutotumori.mi.it. 8. Medical Oncology Unit, Campus Biomedico University Hospital, Rome, Italy. Electronic address: D.Santini@unicampus.it. 9. Medical Oncology Unit, Campus Biomedico University Hospital, Rome, Italy. Electronic address: G.Armento@unicampus.it.
Abstract
INTRODUCTION: Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon. METHODS: The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered. CONCLUSIONS: In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.
INTRODUCTION:Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon. METHODS: The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered. CONCLUSIONS: In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.